Skip to main content

Acquiring Expertise for Improved Patient Outcomes in Immune Thrombocytopenia

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians pertaining to the topic of improved patient outcomes in immune thrombocytopenia (ITP).   Immune thrombocytopenia is a heterogenous disorder in which patients develop an autoimmune response to platelets that results in severe cytopenia and places them at risk for bleeding events. The lack of specific criteria makes diagnosis challenging for clinicians, and understanding the patho...

Continue reading

Improving Comprehension of Graft-Versus-Host-Disease for Enhanced Patient Outcomes

Recently, i3 Health provided an educational activity that challenged knowledge gaps experienced by clinicians regarding improved patient outcomes in graft-versus-host disease (GVHD).   Graft-versus-host disease is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality. Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents within t...

Continue reading

Practice-Changing Proficiency for the Management of Marginal Zone Lymphoma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding new clinical perspectives in the management of marginal zone lymphoma (MZL).   Marginal zone lymphoma comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs). According to the Leukemia and Lymphoma Society®, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from ...

Continue reading

Increasing Knowledge to Improve Patient Outcomes in Multiple Myeloma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding practice-changing strategies for improved patient outcomes in multiple myeloma.   Multiple myeloma is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. Approximately 35,780 new cases of multiple myeloma are expected to occur in the United States this year, and around 12,540 people are likely to die of...

Continue reading

Addressing Knowledge Gaps in the Treatment of Advanced Endometrial Cancer

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding emerging checkpoint inhibitor–based strategies for advanced endometrial cancer.   Cancer of the uterine corpus is the most common cancer of the female genital tract, with an estimated 67,880 new cases diagnosed and 13,250 deaths annually in the United States. Since more than 90% of cases occur in the endometrium, cancer of the uterine corpus is often referred to as end...

Continue reading

i3 Health’s Survey of Urologists Reveals Key Insights Into Learning Preferences

A survey conducted by i3 Health at the Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 18 to 22, 2023, in Tucson, Arizona, has provided valuable insights into urologists' preferred formats and desired topics of continuing medical education (CME) activities, as well as the most important factors they consider when choosing such activities. Additionally, survey participants were asked an additional set of questions regarding their confidence and comf...

Continue reading

Enhancing Knowledge of Small Cell Lung Cancer Treatment and Management

An educational activity offered by i3 Health has provided significant knowledge gains regarding strategies to enhance the clinical outcomes of patients with extensive-stage small cell lung cancer (SCLC) Among the 238,340 new cases of lung cancer reported in the United States each year, approximately 14% of cases are classified as small cell, a more aggressive subtype compared with its non–small cell counterpart. Most patients present with advanced or metastatic disease, making systemic therapy t...

Continue reading

Significant Knowledge Gains for the Diagnosis and Management of T-Cell Lymphoma

Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding the diagnosis and evidence-based management of T-cell lymphoma (TCL). T-cell lymphoma is an uncommon subtype accounting for approximately 7% of all cases of non-Hodgkin lymphoma in the United States. Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL ...

Continue reading

Confronting Knowledge Gaps in Rare Hematologic Malignancies

In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians regarding hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM).  According to the Leukemia and Lymphoma Soc...

Continue reading

Enhanced Proficiency for Treatment Paradigms in Advanced Hepatocellular Carcinoma

i3 Health recently provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding treatment paradigms in advanced hepatocellular carcinoma (HCC).   Liver cancer is the sixth most common tumor type and the third leading cause of cancer-related death worldwide. The American Cancer Society estimates that in the United States, 41,210 new cases will be diagnosed and 29,380 people will die of the disease this year alone. Hepatocellular carcinoma is the mos...

Continue reading

Assessing Proficiency in Squamous Non–Small Cell Lung Cancer Management

i3 Health recently provided an online continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity that has challenged the health care team's proficiency in managing metastatic squamous non–small cell lung cancer (NSCLC). Lung cancer is the second most common cancer in the United States between both men and women, with the American Cancer Society estimating a total of 238,340 new cases being diagnosed and 127,070 deaths occurring throughout 2023. Appr...

Continue reading

Knowledge Gains for Immunotherapeutic Strategies in Cervical Cancer

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity, which was presented as both a Video Viewpoint Strategy Session and a podcast, provided significant gains in proficiency amongst the health care professionals who participated....

Continue reading

Educational Advancements Made in Treatment of Merkel Cell Carcinoma

i3 Health has provided a continuing medical education/nursing continuing professional development (CME/NCPD)–approved activity, Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma, that enabled the health care team to acquire significant gains in proficiency and knowledge for treating their patients with Merkel cell carcinoma (MCC). Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromi...

Continue reading

Enhancing Treatment and Patient-Care Proficiency in Multiple Myeloma

i3 Health has provided a nursing continuing professional development (NCPD)–approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, during which the health care team was challenged to address knowledge gaps experienced in this field. Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites. The American Cancer Society approximates 35,730 new cases of MM to be...

Continue reading

Addressing Knowledge Gaps in Management of Tumor Lysis Syndrome

Recently, i3 Health provided a continuing medical education/nursing continuing professional development/continuing pharmacy education (CME/NCPD/CPE)–approved activity, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies, during which clinicians' knowledge gaps were challenged and knowledge gains were achieved. Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor c...

Continue reading

Addressing Knowledge Gaps in Metastatic Triple-Negative Breast Cancer Treatment and Care

An educational activity provided by i3 Health has delivered significant improvement in knowledge regarding treatment advances and personalized care for patients with metastatic triple-negative breast cancer (TNBC). Breast cancer is the most commonly diagnosed cancer and the second-leading cause of cancer-related death among women in the United States. Approximately 15% of cases are classified as triple-negative, lacking expression of estrogen, progesterone, and human epidermal growth factor 2 (H...

Continue reading

Bridging Knowledge Gaps for Treatment of Immune Thrombocytopenia

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by nursing staff regarding updated treatment options and optimal patient care for immune thrombocytopenia (ITP). ITP is an autoimmune platelet disorder in which the blood does not clot normally as a result of a low platelet count, causing bruising and bleeding. Research has shown that the burden of ITP is significant; in a survey of more than 1,300 patients from 13 different countries, 36% reported a hi...

Continue reading

Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer

An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer death. The American Cancer Society has estimated that in 2022 there will be 287,580 new cases of invasive breast cancer, with 43,250 of these cases resul...

Continue reading

Conquering Knowledge Gaps Concerning Therapeutic Advances in T-Cell Lymphoma

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding therapeutic advances in T-cell lymphoma (TCL). T-cell lymphoma is a rare type of non-Hodgkin lymphoma with many different subtypes, including peripheral TCL, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic TCL, and cutaneous TCL. TCL makes up less than 15% of total non-Hodgkin lymphomas. Mycosis fungoides (MF), the most common form of cutaneous TCL, frequently mi...

Continue reading

Addressing Knowledge Gaps in the Treatment of Metastatic Colorectal Cancer

An educational activity provided by i3 Health has revealed significant learning gains in the knowledge of novel treatment strategies for metastatic colorectal cancer (mCRC). The activity was presented virtually at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2020 and was made available as an enduring online activity. Colorectal cancer is the second leading cause of cancer death among women and men in the United States and is the third most diagnosed cancer worldwide. In the...

Continue reading